702P + 767A

702P + 767A is an experimental combination therapy consisting of two modified U1 small nuclear RNA (snRNA) constructs, U1-702P and U1-767A, designed to inhibit the expression of the human chorionic gonadotropin beta (hCGβ) subunit. This approach, known as U1 snRNA-mediated gene silencing or U1 interference (U1i), involves modifying the 5' end of the U1 snRNA to be complementary to the polyadenylation (polyA) signal or terminal exon of a target pre-mRNA. By binding to these specific sites (at positions 702 and 767 of the hCGβ transcript), the modified U1 snRNAs prevent proper 3' end processing and polyadenylation, leading to mRNA degradation and a subsequent reduction in hCGβ protein levels. This suppression of hCGβ has been demonstrated to trigger apoptosis and inhibit cell growth in malignant cells, such as cervical cancer cells, identifying it as a potential strategy for targeted cancer gene therapy in hCG-secreting malignancies.

Other names

U1 snRNA-702PU-1 snRNA-702PU 1 snRNA-702PU1 snRNA-767AU-1 snRNA-767AU 1 snRNA-767A